Zoledronic Acid: A Review of its Use in the Treatment of Paget's Disease of Bone

Authors: Keating, Gillian M.1; Scott, Lesley J.1

Source: Drugs, Volume 67, Number 5, 2007 , pp. 793-804(12)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The third-generation, nitrogen-containing bisphosphonate zoledronic acid (Aclasta®) is approved in the EU for the treatment of Paget's disease of bone. Results of well designed trials show that a single intravenous dose of zoledronic acid 5mg is effective and well tolerated in the treatment of Paget's disease of bone. A single intravenous dose of zoledronic acid was associated with a significantly higher therapeutic response rate and a more rapid reduction in bone turnover than that achieved with 60 days of oral risedronic acid. Moreover, biochemical remission was sustained after 24 months of follow-up in zoledronic acid recipients. Preliminary results suggest that zoledronic acid is a cost-effective option in Paget's disease of bone. Thus, zoledronic acid is an important first-line treatment for Paget's disease of bone.

Keywords: Adis Drug Evaluations; Paget's disease; Zoledronic acid

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$68.55 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A